WO2007087524A3 - Treatment of acute respiratory distress syndrome - Google Patents

Treatment of acute respiratory distress syndrome Download PDF

Info

Publication number
WO2007087524A3
WO2007087524A3 PCT/US2007/060902 US2007060902W WO2007087524A3 WO 2007087524 A3 WO2007087524 A3 WO 2007087524A3 US 2007060902 W US2007060902 W US 2007060902W WO 2007087524 A3 WO2007087524 A3 WO 2007087524A3
Authority
WO
WIPO (PCT)
Prior art keywords
respiratory distress
distress syndrome
acute respiratory
treatment
phospholipid
Prior art date
Application number
PCT/US2007/060902
Other languages
French (fr)
Other versions
WO2007087524A2 (en
Inventor
Edmund A Egan
Bruce Holm
Original Assignee
Ony Inc
Edmund A Egan
Bruce Holm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/002423 external-priority patent/WO2007084136A2/en
Application filed by Ony Inc, Edmund A Egan, Bruce Holm filed Critical Ony Inc
Priority to JP2008552543A priority Critical patent/JP2009526763A/en
Priority to EP07717366A priority patent/EP1976535A2/en
Priority to BRPI0706723-2A priority patent/BRPI0706723A2/en
Priority to CA002637644A priority patent/CA2637644A1/en
Priority to AU2007208145A priority patent/AU2007208145A1/en
Publication of WO2007087524A2 publication Critical patent/WO2007087524A2/en
Publication of WO2007087524A3 publication Critical patent/WO2007087524A3/en
Priority to IL192121A priority patent/IL192121A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patients suffering from acute respiratory distress syndrome or acute lung injury are treated by administering to the patients a therapeutically effective dosage of a surfactant that includes SP-B and phospholipid at a concentration of SP-B relative to concentration of phospholipid that is sufficient to produce detectable SP-B dependent activity.
PCT/US2007/060902 2006-01-23 2007-01-23 Treatment of acute respiratory distress syndrome WO2007087524A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2008552543A JP2009526763A (en) 2006-01-23 2007-01-23 Treatment of acute respiratory distress syndrome
EP07717366A EP1976535A2 (en) 2006-01-23 2007-01-23 Treatment of acute respiratory distress syndrome
BRPI0706723-2A BRPI0706723A2 (en) 2006-01-23 2007-01-23 process to treat a patient suffering from lung disease that requires the use of mechanical ventilation to sustain breathing
CA002637644A CA2637644A1 (en) 2006-01-23 2007-01-23 Treatment of acute respiratory distress syndrome
AU2007208145A AU2007208145A1 (en) 2006-01-23 2007-01-23 Treatment of acute respiratory distress syndrome
IL192121A IL192121A0 (en) 2006-01-23 2008-06-12 Treatment of acute respiratory distress syndrdme

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76125006P 2006-01-23 2006-01-23
PCT/US2006/002423 WO2007084136A2 (en) 2006-01-23 2006-01-23 Treatment of acute respiratory distress syndrome
USPCT/US2006/02423 2006-01-23
US60/761,250 2006-01-23

Publications (2)

Publication Number Publication Date
WO2007087524A2 WO2007087524A2 (en) 2007-08-02
WO2007087524A3 true WO2007087524A3 (en) 2007-10-18

Family

ID=38089182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/060902 WO2007087524A2 (en) 2006-01-23 2007-01-23 Treatment of acute respiratory distress syndrome

Country Status (8)

Country Link
EP (1) EP1976535A2 (en)
JP (1) JP2009526763A (en)
KR (1) KR20080090442A (en)
AU (1) AU2007208145A1 (en)
BR (1) BRPI0706723A2 (en)
CA (1) CA2637644A1 (en)
IL (1) IL192121A0 (en)
WO (1) WO2007087524A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253003T3 (en) * 1998-11-10 2006-05-16 Altana Pharma Ag TREATMENT EQUIPMENT CONTAINING COMPOSITIONS BASED ON PULMONARY TENSIOACTIVE AGENTS.
ATE468131T1 (en) * 2001-10-11 2010-06-15 Nycomed Gmbh NEW USE OF LUNG SURFACTANT

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAITSMA J J ET AL: "Surfactant therapy for acute lung injury/acute respiratory distress syndrome", CURRENT OPINION IN CRITICAL CARE 2004 UNITED STATES, vol. 10, no. 1, 2004, pages 18 - 22, XP008081891, ISSN: 1070-5295 *
NOTTER ROBERT H ET AL: "Component-specific surface and physiological activity in bovine-derived lung surfactants.", CHEMISTRY AND PHYSICS OF LIPIDS JAN 2002, vol. 114, no. 1, January 2002 (2002-01-01), pages 21 - 34, XP002444802, ISSN: 0009-3084 *
WILLSON D: "Calfactant.", EXPERT OPINION ON PHARMACOTHERAPY SEP 2001, vol. 2, no. 9, September 2001 (2001-09-01), pages 1479 - 1493, XP008081886, ISSN: 1465-6566 *
WILLSON DOUGLAS F ET AL: "Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial.", JAMA : THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 26 JAN 2005, vol. 293, no. 4, 26 January 2005 (2005-01-26), pages 470 - 476, XP002444799, ISSN: 1538-3598 *

Also Published As

Publication number Publication date
JP2009526763A (en) 2009-07-23
EP1976535A2 (en) 2008-10-08
WO2007087524A2 (en) 2007-08-02
BRPI0706723A2 (en) 2011-04-05
IL192121A0 (en) 2008-12-29
AU2007208145A1 (en) 2007-08-02
CA2637644A1 (en) 2007-08-02
KR20080090442A (en) 2008-10-08

Similar Documents

Publication Publication Date Title
GB0410266D0 (en) Treatment of apoptosis
DE602005026007D1 (en) OPIOIDES FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD)
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
NO20072920L (en) Combination of Methylxanthine Compounds and Steroids to Treat Chronic Respiratory Diseases
BRPI0806392A8 (en) use of aclidinium, aclidinium, treatment or prevention method and pharmaceutical composition
TW200716145A (en) Use of LGG in the manufacture of a medicament for the prevention or treatment of respiratory allergies
NO20070597L (en) Medication centers to treat chronic respiratory disease.
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
NO20064964L (en) Treatment of impaired respiratory function
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2011085256A3 (en) Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent
EA201170405A1 (en) MONOTHERPENES FOR THE TREATMENT OF DISEASES OF RESPIRATORY TRACT, IN PARTICULAR, BRONCHOPULMANTS AND DISEASES
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
BR0005797A (en) Methods for the treatment of sexual dysfunction with apomorphine at specified plasma concentration levels
TW200635574A (en) Use of a therapeutically effective amount of DHA and ARA in the manufacture of a medicament for the prevention or treatment of respiratory infections in infants
WO2009006246A8 (en) Use of tight junction antagonists in the treatment of acute long injury and acute respiratory distress syndrome
WO2007035879A3 (en) Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm
WO2007084136A3 (en) Treatment of acute respiratory distress syndrome
WO2007095609A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder
ATE502637T1 (en) MEDICATIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE USING AN ANTICHOLINERGIC

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780001758.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007208145

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 569243

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2007208145

Country of ref document: AU

Date of ref document: 20070123

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007717366

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2637644

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020087017896

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008552543

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: PI0706723

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080723